GX-19

{{short description|Vaccine candidate against COVID-19}}

{{Use dmy dates|date=April 2021}}

{{Infobox drug

| Verifiedfields =

| verifiedrevid =

| drug_name =

| INN =

| type = vaccine

| image =

| alt =

| caption =

| target = SARS-CoV-2

| vaccine_type = dna

| pronounce =

| tradename =

| Drugs.com =

| MedlinePlus =

| licence_EU =

| licence_US =

| pregnancy_AU =

| pregnancy_category =

| legal_AU =

| legal_AU_comment =

| legal_BR =

| legal_BR_comment =

| legal_CA =

| legal_UK =

| legal_US =

| legal_UN =

| legal_NZ =

| legal_status =

| routes_of_administration = Intramuscular

| CAS_number =

| ATCvet =

| ATC_prefix =

| ATC_suffix =

| PubChem =

| DrugBank = DB15891

| synonyms = GX-19N

}}

{{COVID-19 pandemic sidebar}}

GX-19 is a COVID-19 vaccine candidate developed by Genexine consortium.{{cite web |title=Safety and Immunogenicity Study of GX-19, a COVID-19 Preventive DNA Vaccine in Healthy Adults |url=https://clinicaltrials.gov/ct2/show/NCT04445389 |website=ClinicalTrials.gov |publisher=United States National Library of Medicine |id=NCT04445389 |date=24 June 2020 |access-date=14 July 2020 |archive-date=11 October 2020 |archive-url=https://web.archive.org/web/20201011084931/https://clinicaltrials.gov/ct2/show/NCT04445389/ |url-status=live }}{{cite journal |title=Safety and Immunogenicity Study of GX-19N, a COVID-19 Preventive DNA Vaccine in Healthy Adults |url=https://clinicaltrials.gov/ct2/show/NCT04715997 |website=clinicaltrials.gov |date=18 January 2021 |publisher=United States National Library of Medicine |access-date=16 March 2021 }}{{cite news | title=S. Korea's Genexine begins human trial of coronavirus vaccine |url=https://www.reuters.com/article/health-coronavirus-genexine-vaccine-idUSL4N2DW1T3 |access-date=25 June 2020 |publisher=Reuters |date=19 June 2020 |archive-date=11 October 2020 |archive-url=https://web.archive.org/web/20201011084934/https://www.reuters.com/article/health-coronavirus-genexine-vaccine-idUSL4N2DW1T3/ |url-status=live }}{{cite news |title=Genexine consortium's Covid-19 vaccine acquires approval for clinical {{sic|hide=y|trails}} in Korea |url=https://www.ivi.int/genexine-consortiums-covid-19-vaccine-acquires-approval-for-clinical-trails-in-korea/ |date=11 June 2020 |access-date=1 August 2020}}

It is a DNA-based vaccine that encodes the SARS-CoV-2 spike protein.{{cite journal | vauthors = Seo YB, Suh YS, Ryu JI, Jang H, Oh H, Koo BS, Seo SH, Hong JJ, Song M, Kim SJ, Sung YC | display-authors = 6 | title = Soluble Spike DNA Vaccine Provides Long-Term Protective Immunity against SARS-CoV-2 in Mice and Nonhuman Primates | journal = Vaccines | volume = 9 | issue = 4 | date = March 2021 | page = 307 | pmid = 33804981 | pmc = 8063950 | doi = 10.3390/vaccines9040307 | url = | doi-access = free }}